Newsfeed

Review Of Healthcare Consolidation

Excellent Health Affairs Forefront Blog on the impacts of healthcare consolidation. A good read. As the authors note:

• Consolidation is a main driver of increased healthcare costs.
• Horizontal hospital consolidation increases hospital prices 20 to 40%.
• 90% of hospital markets are highly concentrated.
• Hospital acquisition of providers means 55% of all doctors are now employed by hospitals and health systems. This changes practice patterns to higher cost settings.
• Public equity continues to grow in healthcare.

The authors recommend a series of changes to strengthen oversight:

• Taking steps to make it easier to block anticompetitive mergers.
• Refining payments in traditional Medicare to dissuade overpayments related to acquisitions, including moving to site-neutral payments.
• Refining the minimum medical loss ratio (MLR) formula to ensure Medicare Advantage (MA) cannot shuttle monies to plan-owned physician entities to get around the MLR requirement.
• Instituting better transparency on acquisitions and consolidations.

(Article may require a subscription.)

#antitrust #manda #acquisitions #mergers #healthcare

https://www.healthaffairs.org/content/forefront/rise-health-care-consolidation-and-do

Oscar Worried About Sunset of Exchange Premium Subsidy Enhancement

Insurtech Oscar Health is worried about the potential sunset of the enhanced premium subsidies in the Exchanges. Exchange enrollment has reached 21.3 million with the enhanced subsidies, the loss of Medicaid eligibility through the reintroduction of redeterminations, and general pro-coverage policies of the Biden administration.

Oscar could lose 15% to 20% of its enrollment. Oscar is focused on Exchange enrollment. The nation’s uninsured rate has increased already due to Medicaid coverage losses. The increase in the number of uninsured could worsen with the sunset of the enhanced premium subsidies.

The Urban Institute found that the enhanced subsidies will lead to 7.2 million more people receiving subsidized Marketplace coverage and 4.0 million fewer people being uninsured in 2025. It also found that the 7.2 million in added enrollment also will reduce insurer premium rates by 5 percent on average. The sunset of the subsidies would reduce all of this. Not extending the subsidies in 2024 will upend the preparation process for the 2026 benefit year.

(Articles may require a subscription.)

Additional article: https://www.healthaffairs.org/content/forefront/delays-extending-enhanced-marketplace-subsidies-would-raise-premiums-and-reduce

#exchanges #aca #obamacare #oscarhealth

https://www.modernhealthcare.com/insurance/cigna-humana-oscar-health-centene-clover-wells-fargo-morgan-stanley-conference

Cigna Focuses On Its Services Entity’s Growth

Cigna CEO David Cordani has sent a strong message that Cigna’s focus is on Evernorth, its services entity.  Cordani says its pharmacy benefits manager (PBM), Express Scripts, and specialty pharmacy are strong focuses moving forward. They are both housed in Evernorth.

The attention makes sense.  Evernorth has grown tremendously and has been a huge contributor to margin.  The attention to drug costs, including creative ways to address the growth of weight-loss drugs and transitioning to biosimilars, is important. 

At the same time, Cigna will see continued political pressure on the market size of its PBM. PBM reform legislation is becoming more and more likley this year. Cigna seems to think the rise of transparency will not disrupt Express Scripts placement in the market right now.

Additional article: https://www.beckerspayer.com/payer/cigna-ceo-expect-choppiness-in-glp-1-coverage.html

(Some articles may require a subscription.)

#cigna #pbms #drugpricing #biosimilars #weightlossdrugs

https://www.modernhealthcare.com/insurance/cigna-evernorth-health-services-specialty-pharmacy-pbm-david-cordani-morgan-stanley

Bad News on 2025 Medicare Advantage Begins To Roll Out

Humana has reaffirmed its full-year guidance but gave details on the retrenchment it is doing in Medicare Advantage (MA) for 2025.  As expected, Humana announced the paring back of benefits, higher premiums, and the exit from geographies.

Humana is leaving 13 markets next year because they are not profitable or poorly profitable.  In other areas, Humana is staying in but eliminating certain plans with high medical expense, which will diminish choices. Humana says about 560,000 members, or 10% of its individual MA enrollment, would be impacted by the cutbacks. About half of those will stay in Humana in other plans. That is about what Humana said it would lose earlier this year – a couple hundred thousand members.

Other big plans are cutting back, too.  Centene is leaving certain markets, cutting benefits, and raising premiums. Even Humana, who is bullish on MA in 2025, will pare back.

Additional article: https://www.modernhealthcare.com/insurance/humana-medicare-advantage-markets-2025

(Some articles may require a subscription.)

#medicareadvantage #humana

https://www.fiercehealthcare.comV/payers/humana-exiting-medicare-advantage-13-markets

BEA Finds Drug Price Increase Differences With And Without Rebates Factored In

An interesting study from the Bureau of Economic Analysis (BEA), which set out to study whether annual drug price increases are different when factoring in rebates between drug makers and pharmacy benefits managers (PBMs) or health plans. The BEA compared claims data with rebate estimates from 2007 to 2020.

It found something very interesting. Retail pharmacy prices increased by 9.1% each year. Negotiated prices, which include rebates, grew a more modest 4.3% per year. The issue here is that rebates do not regularly make it in full or sometimes even in part from the pockets of PBMs to either employer groups or to patients at the point of sale. Pointing to this is the fact that in 2016, patient out-of-pocket spending rose while negotiated cost growth largely remained flat. The increase in out-of-pocket costs is likely attributable to growing deductibles and co-insurance, which are often set based on list price.

All this shows the need to reform our opaque drug supply channel and eliminate rebates through drug price negotiations.

#drugpricing #ira #branddrugmakers #pbms

https://www.fiercehealthcare.com/finance/out-pocket-spending-prescriptions-grew-even-after-accounting-rebates-study